Skip to content
Home
Discovering Seelos
Our Focus
Our Seelos Management Team
Our Board of Directors
Careers
Pipeline
SLS-002 (intranasal ketamine)
Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD)
SLS-003 (sublingual ketamine)
SLS-004 (gene therapy)
SLS-005 (trehalose)
SLS-007 (peptidic inhibitor)
Patients and Caregivers
Investors and Media
Overview and Financials
Corporate Governance
Press Releases
SEC Filings
Stock Information
Home
Discovering Seelos
Our Focus
Our Seelos Management Team
Our Board of Directors
Careers
Pipeline
SLS-002 (intranasal ketamine)
Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD)
SLS-003 (sublingual ketamine)
SLS-004 (gene therapy)
SLS-005 (trehalose)
SLS-007 (peptidic inhibitor)
Patients and Caregivers
Investors and Media
Overview and Financials
Corporate Governance
Press Releases
SEC Filings
Stock Information
Panel Replay from Maxim Group LLC and M-Vest’s Advances in Mental Health Virtual Conference on 9/22/2021
Uncategorized
https://m-vest.com/insights/marketpulse/advances-in-mental-health-panel-replays
by
seelostherapeutics
on October 1, 2021
0
Post navigation
Previous:
Previous post:
Archived webcast from Virtual Cantor Global Healthcare Conference 9/29/2021
Next:
Next post:
March 10, 2022: HEALEY ALS Platform Trial Weekly Q&A Webinar with Warren Wasiewski, MD of Seelos Therapeutics and Shafeeq Ladha, MD, Regimen E Co-Lead, discussing the science behind trehalose (SLS-005)
Search for:
Recent Posts
Jefferies Healthcare Conference Webcast from 6/10/2022
LifeSci KOL Event: Suicidal Patients in the ED from 4/25/2022
March 10, 2022: HEALEY ALS Platform Trial Weekly Q&A Webinar with Warren Wasiewski, MD of Seelos Therapeutics and Shafeeq Ladha, MD, Regimen E Co-Lead, discussing the science behind trehalose (SLS-005)
Archives
June 2022
April 2022
March 2022
October 2021
June 2021
April 2019
March 2019
February 2019
December 2018
